Clinical Trials Browser

HER2-positive Gastric Cancer × tislelizumab × Clear all

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1/2 Unknown

Gastrointestinal

HER2-positive Gastric Cancer